What You Need To Know About the AREXVY RSV Vaccine + Deceitful Language

Dr. Jessica Rose’s analysis of the AREXVY RSV vaccine is shocking. She shares the details of her findings — adverse events, ingredients, experimentation, efficacy — in this episode of ‘Good Morning CHD.’ Viewers also hear an important conversation about placebos. Then, Joshua Coleman gives a legislative update. Tune in!

*The opinions expressed by the hosts and guests in this show are not necessarily the views of Children’s Health Defense.

DonateJoin Our List

Resources

King Charles III Launches ‘Climate Clock’ That ‘Tells Us What to Do and by When'

King Charles: Climate CATASTROPHE Countdown Clock

CONGRESSIONALLY MANDATED RESEARCH PLAN AND AN INITIAL RESEARCH GOVERNANCE FRAMEWORK RELATED TO SOLAR RADIATION MODIFICATION

Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above | Clinical Trials.gov

'Reckless in the Extreme': FDA Panel Recommends New RSV Shot for Use in Healthy Infants

‘Respiratory Syncytial Virus Vaccine’ Package Insert | FDA

Now Approved | AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted)

'Bombshell' Study of Pfizer COVID Vaccine Suggests Some People Got Highly Dangerous Shots, Others Got a Placebo

Gates Commits $400 Million to Test New TB Vaccine on 26,000 People in Africa and Southeast Asia